GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Petros Pharmaceuticals Inc (NAS:PTPI) » Definitions » Degree of Financial Leverage

Petros Pharmaceuticals (Petros Pharmaceuticals) Degree of Financial Leverage : 0.48 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Petros Pharmaceuticals Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Petros Pharmaceuticals's Degree of Financial Leverage for the quarter that ended in Mar. 2024 was 0.48. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for Petros Pharmaceuticals's Degree of Financial Leverage or its related term are showing as below:

PTPI's Degree of Financial Leverage is ranked better than
72.17% of 1035 companies
in the Drug Manufacturers industry
Industry Median: 0.94 vs PTPI: 0.48

Petros Pharmaceuticals Degree of Financial Leverage Historical Data

The historical data trend for Petros Pharmaceuticals's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Petros Pharmaceuticals Degree of Financial Leverage Chart

Petros Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Degree of Financial Leverage
- -8.25 1.12 0.14 0.57

Petros Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.14 0.05 1.22 0.57 0.48

Competitive Comparison of Petros Pharmaceuticals's Degree of Financial Leverage

For the Drug Manufacturers - Specialty & Generic subindustry, Petros Pharmaceuticals's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Petros Pharmaceuticals's Degree of Financial Leverage Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Petros Pharmaceuticals's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where Petros Pharmaceuticals's Degree of Financial Leverage falls into.



Petros Pharmaceuticals Degree of Financial Leverage Calculation

Petros Pharmaceuticals's Degree of Financial Leverage for the quarter that ended in Mar. 2024 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -7.37 (Mar. 2024) / -10.26 (Mar. 2023) - 1 )/( -8.426 (Mar. 2024) / -20.663 (Mar. 2023) - 1 )
=-0.2817/-0.5922
=0.48***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Petros Pharmaceuticals  (NAS:PTPI) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


Petros Pharmaceuticals Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of Petros Pharmaceuticals's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Petros Pharmaceuticals (Petros Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1185 Avenue of the Americas, 3rd Floor, New York, NY, USA, 10036
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. It focuses on identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including erectile dysfunction, peyronie's disease, hormone health and substance use disorders. The company's operating segment includes Prescription Medications and Medical Devices. It generates maximum revenue from the Medical Devices segment. The Prescription Medications segment consists primarily of operations related to Stendra, which is sold generally in the United States, and H100 for the treatment of Peyronie's disease.
Executives
Wayne Remell Walker director 1515 MARKET STREET, SUITE 1720, PHILADELPHIA PA 19103
Greg Bradley director 200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
John D Shulman director, 10 percent owner
Jcp Iii Sm Aiv, L.p. 10 percent owner 5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Juggernaut Partners Iii Gp, L.p. 10 percent owner 5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Juggernaut Partners Iii Gp, Ltd. 10 percent owner 5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Metp Holdings Llc 10 percent owner 5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Joshua Silverman director IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Bruce Bernstein director 780 THIRD AVENUE, 12TH FLOOR, NEW YORK NY 10017
Keith Lavan officer: Chief Financial Officer 200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
Fady Boctor officer: Pres. & Chief Comm. Officer 200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
Andrew Gesek officer: President, Timm Medical 200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
Metuchen Therapeutics, Llc 10 percent owner 5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Mitchell Arnold officer: Prin. Acct. Off/Prin. Fin. Off 200 ROUTE 9 NORTH, SUITE 500, MANALAPAN NJ 07726

Petros Pharmaceuticals (Petros Pharmaceuticals) Headlines

From GuruFocus

Petros Pharmaceuticals Announces $7.5 Million Offering

By PRNewswire PRNewswire 12-22-2021

Petros Pharmaceuticals Announces Reverse Stock Split

By ACCESSWIRE ACCESSWIRE 11-30-2022